Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Reports 2025 Net Loss of $32.8 Million, Up From $24.4 Million

Negative Impact 3 of 5 earnings Written later

DiaMedica Therapeutics reported full-year 2025 results showing a wider net loss of $32.8 million, or $0.70 per share, compared with $24.4 million, or $0.60 per share, in 2024, as research and development and general and administrative costs rose. The company ended 2025 with $59.9 million in cash and short-term investments, which it says will fund operations through the second half of 2027, after share sales in July 2025 and under its at-the-market program.

Key points

  • Net loss for 2025 was $32.8 million, or $0.70 per share, versus $24.4 million, or $0.60 per share, in 2024.
  • Research and development expenses rose to $24.6 million from $19.1 million, driven mainly by the ReMEDy2 trial and its global expansion.
  • General and administrative expenses rose to $9.8 million from $7.6 million, including higher share-based compensation.
  • Cash and short-term investments were $59.9 million at December 31, 2025, up from $44.1 million a year earlier.

The filing

CompanyDiaMedica Therapeutics Inc. (DMAC)
Form8-K, current report
Filed with the SECMar 30, 2026, 6:40 PM ET
Accession number0001437749-26-010409

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.